Page 37 - 77_01

JOSÉ
LUIS
VILA

parámetros
farmacocinéticos,
farmacodinámicos
y
de
seguridad
están
permitiendo

desarrollar
terapéuticas
que
pasen
a
fase
clínica
para
cáncer
y
otras
patologías.

8. REFERENCIAS

1. Fire, et al. (1998) Potent and specific genetic interference by double-stranded RNA in
Caenorhabditis elegans. Nature. 391: 806-811.

2. A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal
Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration
(AMD). ClinicalTrials.gov.

3. A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related
Macular Degeneration. ClinicalTrials.gov.

4. Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic
Macular Edema. ClinicalTrials.gov.

5. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet
AMD (CARBON) ClínicalTrials.gov.

6. Safety and efficacy study of small interfering ribonucleic acid (RNA) molecule (Cand5) to treat
wet age-related macular degeneration.ClinicalTrials.gov.

7. Durcan, N., Murphy, C. & Cryan, A. (2008) Inhalable siRNA: potent as a therapeutic agent in
the lugs. Molecular Pharm. 5(4): 559-566.

8. Phase II Clinical Trial of ALN-RSV01 demonstrates statistically significant anti-viral efficacy.
Estudio GEMINI: www.alnylam.com.

9. Immunotherapy of melanoma with tumor antigen RNA and small inhibitory RNA transfected
autologous dendritic cells. ClinicalTrial.gov.

10. Use of SV40 vectors to treat chronic myeloid leukemia (CML): ClinicalTrials.gov.
11. Safety Study of CALAA-01 to Treat Solid Tumor Cancers: ClinicalTrials.gov.
12. Davies, M. E. (2009) The first targeted delivery of siRNA in humans via a self-assembling,

cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3): 659-668.
13. Study with Atu027 in patients with advanced solid cancer. ClinicalTrials.gov.
14. The Role of Aromatic Hydrocarbon Receptor in the Tumorigenesis of Neuroblastoma and Its

Relationship With MYCN Expression: ClinicalTrials.gov.
15. Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable

Adenocarcinoma of the Pancreas Phase I - Multiple Dose Study of siG12D LODER (Local
Drug EluteR) in Patients With Adenocarcinoma of the Pancreas. ClinicalTrials. gov.
16. The Role of Glycosyltransferases in the Oncogenesis of Neuroblastoma. ClinicalTrials.gov.
17. Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
of liposomal siRNA in subjects with high cholesterol. ClinicalTrials.gov.
18. A dose escalation and safety study of I5NP to prevent AKI in patients undergoing major
cardiovascular surgery (QRK.002): ClinicalTrials.gov.
19. I5NP for prophylaxis of delayed graft function in kidney transplantation: ClinicalTrials.gov.
20. Leachman, S. A., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L.,
Boucher, K. M., Hansen, C. D., Eliason, M. J., Srivatsa, G. S., Kornbrust, D. J., Smith, F. J.,
McLean, W. I., Milstone, L. M. & Kaspar, R. L. (2010) First-in-human Mutation-targeted
siRNA Phase Ib Trial of an Inherited Skin Disorder. Mol. Ther. 18(2): 442-446.
21. NUC B1000: http://www.nucleonicsinc.com/clinical/index.html
22. Chen, Y., Chen, G. & Mahato, R. (2008) RNAi for treating hepatitis B viral infection. Pharm
Res. 25 (1): 72-86.
23. SYL040012. Tolerance and Effect on Intraocular Pressure in Subjects With Intraocular Pressure
(IOP) >= 21 mm Hg. ClincalTrials gov.
24. Ray, R. B. & Kanda, T. (2009) Inhibition of HCV replication by small interfering RNA.
Methods Mol. Bio. 510: 251-62.
25. Kim, S. I., Shin, D., Lee, H., Ahn, B. Y., Yoon, Y. & Kim, M. (2009) Targeted delivery of
siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J. Hepatol.
50(3): 479-88.
26. Caldwell, D. J. & Evans J. D. (2008) Developing clinical role of a CCR5 coreceptor antagonist
in HIV-1 infection. Expert Opin. Pharmacother. 9 (18): 3231-3242.
27. Subramanya, S., Kim, S. S., Manjunath, N. & Shankar, P. (2010) RNA-interference based
therapeutics for human inmunodeficiency HIV-1 treatment; synthetic siRNA or vector - based
shRNA. Expert Opin. Biol. Ther. 10(2): 201-213.

46